Tanapat Tassaneeyasin

Tanapat Tassaneeyasin

Auto-generated profile, based on publicly available information

Tanapat Tassaneeyasin

Chakri Naruebodindra Medical Institute, Faculty of Medicine Ramathibodi Hospital, Mahidol University, Samut Prakan, Thailand

Research Focus & Metrics

Academic Career Length

3Years (2024-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
21 May 2024 in PLOS ONE
Verified
Journal Article
Open access
PDF file
TTTanapat Tassaneeyasin
Tanapat Tassaneeyasin
SSSomnuek Sungkanuparph
Somnuek Sungkanuparph
SSSirawat Srichatrapimuk
Sirawat Srichatrapimuk
ACAttawit Charoensri
Attawit Charoensri
KTKanin Thammavaranucupt
Kanin Thammavaranucupt
SKSuppachok Kirdlarp
Suppachok Kirdlarp
Backgrounds: In critically ill patients with COVID-19, secondary infections are potentially life-threatening complications. This study aimed to determine the prevalence, clinical characteristics, and risk factors of CMV reactivation among critically ill immunocompetent patients with COVID-19 pneumonia. Methods: A retrospective cohort study was conducted among adult patients who were admitted to ICU and screened for quantitative real-time PCR for CMV viral load in a tertiary-care hospital during the third wave of the COVID-19 outbreak in Thailand. Cox regression models were used to identify significant risk factors for developing CMV reactivation. Results: A total of 185 patients were studied; 133 patients (71.9%) in the non-CMV group and 52 patients (28.1%) in the CMV group. Of all, the mean age was 64.7±13.3 years and 101 patients (54.6%) were males. The CMV group had received a significantly higher median cumulative dose of corticosteroids than the non-CMV group (301 vs 177 mg of dexamethasone, p0.05). The 90-day mortality rate for all patients was 29.1%, with a significant difference between the CMV group and the non-CMV group (42.3% vs. 24.1%, p = 0.014). Median length of stay was longer in the CMV group than non-CMV group (43 vs 24 days, p<0.001). The CMV group has detectable CMV DNA load with a median [IQR] of 4,977 [1,365–14,742] IU/mL and 24,570 [3,703–106,642] in plasma and bronchoalveolar fluid, respectively. In multivariate analysis, only a cumulative corticosteroids dose of dexamethasone ≥250 mg (HR = 2.042; 95%CI, 1.130–3.688; p = 0.018) was associated with developing CMV reactivation. Conclusion: In critically ill COVID-19 patients, CMV reactivation is frequent and a high cumulative corticosteroids dose is a significant risk factor for CMV reactivation, which is associated with poor outcomes. Further prospective studies are warranted to determine optimal management.

23 February 2024 in Respirology Case Reports
Verified
Journal Article
Open access
TTTanapat Tassaneeyasin
Tanapat Tassaneeyasin
DEDararat Eksombatchai
Dararat Eksombatchai
PCPrawat Chantharit
Prawat Chantharit
ASArunee Singhsnaeh
Arunee Singhsnaeh
VBViboon Boonsarngsuk
Viboon Boonsarngsuk
The Naganishia species is a mycosis, previously classified as a non‐neoformans Cryptococcus species. The increased number of naganishial infections occurs predominantly in immunocompromised conditions, especially in people living with HIV with low CD4 cell count, primary immunodeficiencies, and iatrogenic immunosuppression. The lungs can serve as the primary site of infection, leading to various pulmonary manifestations. However, naganishial pleural effusions are unrecognized and challenged in diagnosis because of their presentation, which can mimic tuberculous pleural effusion. Herein, we report the case of a 53‐year‐old man who had undergone kidney transplantation for more than 2 years and presented with chest tightness and dyspnea. Computed chest tomography demonstrated left pleural nodules and pleural effusion, later confirmed as exudative pleural effusion with a lymphocyte predominance. Pleuroscopy revealed multiple small pleural nodules, and biopsies of these nodules were performed. Naganishia spp. was identified by the 18S rRNA sequencing technique.